DURATION OF PLECONARIL EFFECT ON CYTOCHROME P450 3A ACTIVITY IN HEALTHY ADULTS USING THE ORAL BIOMARKER MIDAZOLAM
Open Access
- 7 February 2006
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 34 (5), 783-785
- https://doi.org/10.1124/dmd.105.007831
Abstract
The objective of this study was to evaluate the duration of oral pleconaril (a picornavirus inhibitor) effect on intestinal and hepatic cytochrome P450 (P450) 3A activity as assessed by oral midazolam. Healthy adults received oral midazolam (0.075 mg/kg) on days 1 (baseline), 7, 9, 13, 20, 27, and 34. Oral pleconaril (400 mg) three times daily for 15 doses was administered on days 2 through 7. Blood samples were collected during each day of midazolam dosing to determine plasma midazolam concentrations. On days 5, 6, and 7, blood samples were collected to determine plasma pleconaril concentrations. Midazolam pharmacokinetics were determined by noncompartmental analyses, with bioequivalence assessed by least-squares geometric mean ratios (LS-GMR) and 90% confidence intervals (90% CI). Eighteen subjects completed the study. Midazolam Cmax (LS-GMR; 90% CI) decreased 24% on day 7 (0.76; 0.66–0.87). Midazolam oral clearance increased 53% on day 7 (1.53; 1.38–1.69). Midazolam oral clearance remained different on days 9 (1.38; 1.25–1.52) and 13 (1.19; 1.07–1.31) versus day 1. Midazolam volume of distribution (1.82; 1.57–2.11) and elimination half-life (1.19; 1.03–1.38) were also different on day 7 in comparison with day 1. Oral pleconaril increased intestinal and hepatic CYP3A activity. The duration of increased CYP3A activity by pleconaril was at least 6 days (but no longer than 13 days) after pleconaril discontinuation.Keywords
This publication has 16 references indexed in Scilit:
- The Effect of Oral Pleconaril on Hepatic Cytochrome P450 3A Activity in Healthy Adults Using Intravenous Midazolam as a ProbeThe Journal of Clinical Pharmacology, 2006
- Pleconaril, a Novel Antipicornaviral AgentPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003
- Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam*Clinical Pharmacology & Therapeutics, 1998
- Inhibition and Induction of Cytochrome P450 and the Clinical ImplicationsClinical Pharmacokinetics, 1998
- Rhinovirus infection associated with serious lower respiratory illness in patients with bronchopulmonary dysplasiaThe Pediatric Infectious Disease Journal, 1997
- Rifampin drastically reduces plasma concentrations and effects of oral midazolamClinical Pharmacology & Therapeutics, 1996
- Human Enterovirus InfectionsPublished by American Society for Microbiology ,1995
- Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampinEuropean Journal of Clinical Pharmacology, 1993
- Urinary excretion of 6?-hydroxycortisol and the time course measurement of enzyme induction in manEuropean Journal of Clinical Pharmacology, 1989
- Some Considerations as to the Determination and Significance of Biologic Half-LifeJournal of Pharmaceutical Sciences, 1971